Waldron Private Wealth LLC Sells 65 Shares of Thermo Fisher Scientific Inc. $TMO

Waldron Private Wealth LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 575 shares of the medical research company’s stock after selling 65 shares during the quarter. Waldron Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $233,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Mondrian Investment Partners LTD lifted its position in Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock worth $106,738,000 after buying an additional 127,357 shares in the last quarter. Caledonia Investments PLC lifted its position in Thermo Fisher Scientific by 11.5% during the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after buying an additional 11,500 shares in the last quarter. Foresight Group Ltd Liability Partnership lifted its position in Thermo Fisher Scientific by 3,242.7% during the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company’s stock worth $29,113,000 after buying an additional 56,747 shares in the last quarter. Advisors Capital Management LLC lifted its position in Thermo Fisher Scientific by 6.7% during the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company’s stock worth $63,201,000 after buying an additional 7,967 shares in the last quarter. Finally, New England Research & Management Inc. lifted its position in Thermo Fisher Scientific by 28.6% during the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company’s stock worth $1,033,000 after buying an additional 567 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,666 shares of company stock worth $13,990,971. Company insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on TMO. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday. Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. TD Cowen boosted their price objective on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research note on Thursday. Evercore ISI boosted their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Finally, Citigroup boosted their price objective on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a research note on Thursday. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $595.75.

Thermo Fisher Scientific Stock Up 0.2%

Shares of TMO opened at $573.07 on Monday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The firm has a market cap of $216.40 billion, a P/E ratio of 33.11, a price-to-earnings-growth ratio of 3.35 and a beta of 0.77. The firm’s 50-day simple moving average is $504.04 and its 200 day simple moving average is $453.56. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the prior year, the business earned $5.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.